Home : October 2018 : October 23, 2018 News : Cyxone Selects First Clinical Site Ahead of Phase 1 Study With T20K in MS

Cyxone Selects First Clinical Site Ahead of Phase 1 Study With T20K in MS

October 23, 2018

STOCKHOLM, Oct. 23, 2018 /PRNewswire/ -- Cyxone AB (publ) announced today that the company has selected the clinical site that will carry out the drug candidate T20K's first in man study. The clinical site located in Western Europe has been carefully evaluated based on a number of crucial ...

https://www.prnewswire.com:443/news-releases/cyxone-selects-first-clinical-site-ahead-of-phase-1-study-with-t20k-in-ms-300735844.html
Other Stories